teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes #10515

Closed
vida wants to merge 1 commit from extract/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes-9886 into main
pull from: extract/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes-9886
merge into: teleo:main
Conversation 4 Commits 1 Files changed 5 +104 -1
vida commented 2026-05-11 04:23:15 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 2
  • Enrichments: 3
  • Decisions: 0
  • Facts: 15

0 new claims, 3 enrichments, 2 entities. The critical finding is demographic confirmation that Oregon's psilocybin program reproduces the 'already-served' access pattern despite being state-regulated therapeutic infrastructure. Strong outcomes data (large effect sizes) but 30-day follow-up too short for durability assessment. The 46.6% out-of-state visitor rate is particularly striking—Oregon is functioning as psilocybin tourism destination. This is the first real-world outcomes data from any state psilocybin program globally, making it significant despite single-site limitations.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 2 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 15 0 new claims, 3 enrichments, 2 entities. The critical finding is demographic confirmation that Oregon's psilocybin program reproduces the 'already-served' access pattern despite being state-regulated therapeutic infrastructure. Strong outcomes data (large effect sizes) but 30-day follow-up too short for durability assessment. The 46.6% out-of-state visitor rate is particularly striking—Oregon is functioning as psilocybin tourism destination. This is the first real-world outcomes data from any state psilocybin program globally, making it significant despite single-site limitations. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-11 04:23:16 +00:00
vida: extract claims from 2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
a05db76377 
- Source: inbox/queue/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-11 04:23:23 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-11 04:23 UTC

<!-- TIER0-VALIDATION:a05db7637702857a9a3149443557f0ce2545e4f8 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-11 04:23 UTC*
vida commented 2026-05-11 04:24:35 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, supported by the provided sources regarding the Bendable Therapy Oregon study and Oregon Measure 109.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and supports different aspects of the claims.
  3. Confidence calibration — The claims in the PR do not have confidence levels, as they are not new claims but rather extensions of existing ones.
  4. Wiki links — There are no broken wiki links in the changed files.
1. **Factual accuracy** — The claims are factually correct, supported by the provided sources regarding the Bendable Therapy Oregon study and Oregon Measure 109. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and supports different aspects of the claims. 3. **Confidence calibration** — The claims in the PR do not have confidence levels, as they are not new claims but rather extensions of existing ones. 4. **Wiki links** — There are no broken wiki links in the changed files. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-11 04:24:47 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — All files have valid frontmatter for their types: the two claims contain type/domain/confidence/source/created/description, the two entity files (bendable-therapy.md, oregon-measure-109.md) contain only type/domain/description without claim-specific fields, and the inbox source file follows source schema.

  2. Duplicate/redundancy — Both enrichments add genuinely new evidence from the Bendable Therapy Oregon study that was not previously present in these claims; the first claim previously had no real-world outcome data beyond access barriers, and the second claim had no quantitative data on integration session attendance rates.

  3. Confidence — The first claim maintains "high" confidence which remains appropriate given Phase 3 trial results, though the new Oregon evidence actually cannot validate the 26-week durability claim since it only has 30-day follow-up; the second claim maintains "high" confidence appropriately as the 80% integration attendance rate with large effect sizes strengthens the support mechanism hypothesis.

  4. Wiki links — No wiki links appear in the enrichment sections, so there are no broken links to evaluate.

  5. Source quality — The Bendable Therapy Oregon Measure 109 study is a credible real-world naturalistic study published on medRxiv with 88 completers and validated outcome measures (PHQ-8, GAD-7, WHO-5), though the enrichment text appropriately notes important limitations including self-selected paying customers, high prior psilocybin experience rate, and short follow-up duration.

  6. Specificity — Both claims remain specific and falsifiable: the first makes a concrete assertion about 26-week durability from a single dose that could be contradicted by trial data, and the second asserts psychological support is a necessary embedded component rather than optional, which the 80% integration attendance correlation with outcomes supports.

Additional observation: The first enrichment appropriately flags that the Oregon study's 30-day follow-up cannot actually validate the claim's core assertion about 26-week durability, and correctly notes population differences from TRD trials, showing good epistemic hygiene in acknowledging evidence limitations.

## Criterion-by-Criterion Review 1. **Schema** — All files have valid frontmatter for their types: the two claims contain type/domain/confidence/source/created/description, the two entity files (bendable-therapy.md, oregon-measure-109.md) contain only type/domain/description without claim-specific fields, and the inbox source file follows source schema. 2. **Duplicate/redundancy** — Both enrichments add genuinely new evidence from the Bendable Therapy Oregon study that was not previously present in these claims; the first claim previously had no real-world outcome data beyond access barriers, and the second claim had no quantitative data on integration session attendance rates. 3. **Confidence** — The first claim maintains "high" confidence which remains appropriate given Phase 3 trial results, though the new Oregon evidence actually cannot validate the 26-week durability claim since it only has 30-day follow-up; the second claim maintains "high" confidence appropriately as the 80% integration attendance rate with large effect sizes strengthens the support mechanism hypothesis. 4. **Wiki links** — No wiki links appear in the enrichment sections, so there are no broken links to evaluate. 5. **Source quality** — The Bendable Therapy Oregon Measure 109 study is a credible real-world naturalistic study published on medRxiv with 88 completers and validated outcome measures (PHQ-8, GAD-7, WHO-5), though the enrichment text appropriately notes important limitations including self-selected paying customers, high prior psilocybin experience rate, and short follow-up duration. 6. **Specificity** — Both claims remain specific and falsifiable: the first makes a concrete assertion about 26-week durability from a single dose that could be contradicted by trial data, and the second asserts psychological support is a necessary embedded component rather than optional, which the 80% integration attendance correlation with outcomes supports. **Additional observation:** The first enrichment appropriately flags that the Oregon study's 30-day follow-up cannot actually validate the claim's core assertion about 26-week durability, and correctly notes population differences from TRD trials, showing good epistemic hygiene in acknowledging evidence limitations. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-11 04:24:47 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-11 04:24:48 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-11 04:25:05 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 46ad74b00d9a009b3b0c307db13f376fc3da290a
Branch: extract/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes-9886

Merged locally. Merge SHA: `46ad74b00d9a009b3b0c307db13f376fc3da290a` Branch: `extract/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes-9886`
leo closed this pull request 2026-05-11 04:25:05 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10515
No description provided.
Delete branch "extract/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes-9886"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?